France· FR:63280448
VYXEOS LIPOSOMAL 44 mg/100 mg, poudre pour solution à diluer pour perfusion
A medicinal product containing cytarabine + chlorhydrate de daunorubicine, registered in France by JAZZ PHARMACEUTICALS IRELAND LIMITED (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CYTARABINE + CHLORHYDRATE DE DAUNORUBICINE
- Manufacturer
- JAZZ PHARMACEUTICALS IRELAND LIMITED (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550588231 flacon en verre de 50 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cytarabine + chlorhydrate de daunorubicine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVYXEOS LIPOSOMALJazz Pharmaceuticals Ireland Ltd, Dublin
- SwitzerlandVyxeos liposomal 44 mg/100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionsdispersionJazz Pharmaceuticals Switzerland GmbH
- FinlandVyxeos liposomalJazz Pharmaceuticals Ireland Limited
- IrelandVyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Ireland Limited
- IcelandVyxeos liposomalJazz Pharmaceuticals Ireland Ltd
- NetherlandsVyxeos liposomal 44 mg/100 mg poeder voor concentraat voor oplossing voor infusieJazz Pharmaceuticals Ireland Limited
- NorwayVyxeos liposomalJazz Pharmaceuticals Ireland Limited
- PolandVyxeos liposomalJazz Pharmaceuticals Ireland Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyxeos Liposomal
- Liechtenstein · Vyxeos Liposomal
- Norway · Vyxeos Liposomal
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b290a5ef-46f7-4b92-86f6-8539ddfdb0c0 GET /v1/drugs/b290a5ef-46f7-4b92-86f6-8539ddfdb0c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63280448",
"date_amm": "2018-08-23",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1308",
"substance": "CYTARABINE + CHLORHYDRATE DE DAUNORUBICINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about cytarabine + chlorhydrate de daunorubicine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.